Axial Spondyloarthritis Drugs Market Value Projected to Expand by 2028

 The global axial spondyloarthritis drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Axial spondyloarthritis is a type of inflammatory arthritis. It primarily affects the spine and the sacroiliac (SI) joints that are connected to the lower spine to the pelvis which results in pain in the lower back, hips, and buttocks. The major factor driving the growth of the market is the new product launches and drug approval across the globe.

For instance, in August 2019, Eli Lilly and Company announced the approval of Taltz (ixekizumab) injection 80 mg/mL from the US Food and Drug Administration (FDA). It is used for the treatment of active ankylosing spondylitis (AS) which is also known as radiographic axial spondyloarthritis (r-axSpA) in adults. Additionally, in June 2020, Novartis announced the approval of Cosentyx (secukinumab) from the US Food and Drug Administration (FDA). It is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).

To Request a Sample of our Report on Axial Spondyloarthritis Drugs Market:  https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drugs-market

Some major players in the market include AbbVie Inc., Novartis International AG, and Johnson & Johnson, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, AbbVie announced the submission of applications to seek approvals for upadacitinib (RINVOQ, 15 mg) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).  Upadacitinib (RINVOQ, 15 mg) is used for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Market Coverage

  • The market number available for – 2022-2028
  • Base year- 2020
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- AbbVie Inc., Novartis International AG, and Johnson & Johnson Services, Inc., among others.

A full Report of Axial Spondyloarthritis Drugs Market is Available @ https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drugs-market

Global Axial Spondyloarthritis Drugs Market Report by Segment

By Type

  • Certolizumab Pegol
  • Etanercept Biosimilar
  • Ixekizumab
  • Secukinumab
  • Others

By Application 

  • Clinic
  • Hospital
  • Homecare

Global Axial Spondyloarthritis Drugs Market Report by Region

 North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe

Asia-Pacific

  • India
  • China
  • Japan
  • South Korea
  • Rest of APAC

Rest of the World

  • Latin America
  • Middle East & Africa

Reasons to buy from us –

  1. We cover more than 15 major industries, further segmented into more than 90 sectors.
  2. More than 120 countries are for analysis.
  3. Over 100+ paid data sources mined for investigation.
  4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404